La Jolla Pharma?s Share Price Halves On Trial End, CEO Departure

La Jolla Pharmaceutical is turning its focus to its lone FDA-approved product and another one in the pipeline after an experimental drug for a rare blood disease failed a late-stage study. On Monday, La Jolla Pharma (NASDAQ: LJPC) said it was halting a clinical trial testing LJPC-401, its drug candidate for iron overload in patients [?]